The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...

Like other vaccines, BNT116 teaches the immune system to recognize a specific thing and realize that it’s bad You can save this article by registering for free here. Or sign-in if you have an ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share ...

including off-the-shelf products BNT111 (advanced melanoma), BNT113 (HPV-positive head and neck cancers), and BNT116 (lung cancer). Of these, BNT111 and BNT113 lead the way, as phase 2 studies ...

The mRNA vaccine, known as BNT116, is being developed by BioNTech and is targeting the treatment of non-small cell lung cancer (NSCLC). The phase 2 trial will recruit 130 participants across seven ...

The investigational lung cancer mRNA immunotherapy for non-small cell lung cancer (NSCLC), known as BNT116, uses messenger RNA (mRNA) to present common tumor markers from NSCLC to the patient’s immune ...

At the end of August 2024, mRNA vaccine leader BioNTech (producer of the “Pfizer vaccine”) announced that it started global clinical trials in 7 countries and 34 research sites for a mRNA-based lung ...

and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat ...